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Summary The fluorometric microculture cytotoxicity assay (FMCA) was employed for analysing the effect of
different chemotherapeutic drug combinations and their single constituents in 44 cases of acute myelocytic
leukaemia (AML). A large heterogeneity with respect to cell kill was observed for all combinations tested, the
interactions ranging from antagonistic to synergistic in terms of the multiplicative concept for drug interac-
tions. However, an.'additive' model provided a significantly better fit of the data compared to the effect of the
most active single agent of the combination (Dmax) for several common antileukaemic drug combinations.
When the two interaction models were related to treatment outcome 38% of the non-responders showed
preference for the additive model whereas the corresponding figure for responders was 80%. Overall, in 248 of
290 (85%) tests performed with drug combinations, there was an agreement between the effect of the
combination and that of the most active single component. Direct comparison of Dmax and the combination
for correlation with clinical outcome demonstrated only minor differences in the ability to predict drug
resistance. The results show that FMCA appear to report drug interactions in samples from patients with
AML in accordance with clinical experience. Furthermore, testing single agents as a substitute for drug
combinations may be adequate for detection of clinical drug resistance to combination therapy in AML.
Chemotherapy for malignant disease has continuously im-
proved over the past decades. At least part of this im-
provement can be attributed to the use of combination
chemotherapy, perhaps most evident in the case of the
leukaemias and the lymphomas (Rankin & Kaye, 1990).
Short-term in vitro drug sensitivity assays have raised the
possibility of predicting clinical outcome and selecting
optimal components for chemotherapeutic protocols for indi-
vidual patients (Bosanquet, 1991; Kern & Weisenthal, 1990;
Hongo et al., 1990; Larsson et al., 1992a; Pieters et al., 1991;
Von Hoff, 1988; Weisenthal & Lippman, 1985). Although the
majority of patients are treated with drug combinations,
these assays most commonly test single agents. For most
solid tumours, the in vitro activity of the most active single
drug measured by clonogenic (Sondak et al., 1988a) and
thymidine assays (Sondak et al., 1988b) has been shown to
closely predict the effect of combinations. However, for
tumours where combination chemotherapy has been more
successful (i.e. lymphomas and leukaemias) this may not be
the case. Undetected interactions between drugs may thus
constitute an important source of false negative test results of
in vitro drug sensitivity assays.
We have previously described the fluorometric microcul-
ture cytotoxicity assay (FMCA) for drug sensitivity testing of
cell lines and tumour cell samples from patients with acute
myelocytic leukaemia (AML; Larsson et al., 1992a; Larsson
& Nygren, 1990). In the present study we employed this
method for the study of drug interactions in AML. The
results show a large variability with respect to the effects of
different drug combinations ranging from antagonistic to
synergistic. In contrast to observations made in solid
tumours (Sondak et al., 1988a; Sondak et al., 1988b) the
effect of some clinically AML active combinations was more
accurately predicted by an additive model of drug interac-
tions. However, despite this, the test result of the most active
single agent could correctly predict the in vitro activity of the
combination in the majority of the cases.
Materials and methods
Leukaemic samples
Totally 44 leukaemic cell samples were obtained from
peripheral blood or bone marrow from 40 adult patients with
newly diagnosed or relapsed AML. Twenty-nine samples
were from previously untreated patients and 15 were from
previously treated patients. Mononuclear cells were ob-
tained by 1,077 g ml-' Ficoll-Isopaque (Pharmacia, Uppsala,
Sweden) density gradient centrifugation. Viability was deter-
mined by trypan blue exclusion test and the density gradient
centrifugation generally yielded cell suspensions of >85%
leukaemic cells as judged by May-Grunwald-Giemsa stained
cytocentrifugate preparations. Culture medium RPMI 1640
medium (Flow, Herts, England) supplemented with 10%
heat-inactivated foetal calf serum (FCS; Flow), 2 mM
glutamine, 50 Lg ml' streptomycin and 60 tLg ml-' penicillin
was used throughout. Cells were cryopreserved in culture
medium containing 10% dimethyl sulfoxide (DMSO) and
50% FCS by initial freezing for 24 h in - 70'C followed by
storage in liquid nitrogen. Both fresh and cryopreserved sam-
ples were used in this study.
Reagents and drugs
Fluorescein diacetate (FDA; Sigma Chem Co, St. Louis,
MO, USA) was dissolved in DMSO (Sigma) and kept frozen
(- 20'C) as a stock solution (10 mg ml-') protected from
light. Drugs were obtained from various sources and were
diluted and tested at the concentrations indicated in Table I.
Empirically derived cut-off concentrations (EDCC) were
selected according to principles described previously and are
in most cases in the range achievable in plasma (Larsson et
al., 1992a). EDCC concentrations of each drug were used in
the combinations (Table II). Experimental plates were
prepared with 20 lpl/well of drug solution at 10 x the desired
final concentration and stored frozen at - 70°C until further
use. The experiments were performed using continuous drug
exposure.
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Table I Origin and concentrations of FMCA drug solutions
Drug Origin Concentrationa Solvent
Ara-C Sigma 0.5 tLg ml-
I PBS
Doxorubicin Adriamycin@9 Farmitalia 0.5 figml-' SW
Daunorubicin Cerubidin®, Rohne-P 0.1 gml-' SW/PBS
VP-16 Vepeside®, Bristol-Myers 5 tLgml-' PBS
Vincristine Oncovin®O, Lilly 0.1 gml-' PBS
Melphalan Alkeran®, Wellcome 2.5 yg ml-' acid etOH
Prednisolon Precortalon®, Organon 10 1gml-' PBS
Mitoxantrone Novantrone®O, Lederle 0.5 Lgml-' PBS
6-TG Sigma 10 g ml-' NaOH/SW
Amsa Amsakrin®, Bristol-Myers 0.5jigml-' SW
aEDCC; Empirically derived cut-offconcentrations for in vitro-in vivo comparison
were established as described previously (Larsson et al., 1992a). SW = sterile water,
etOH = absolute ethanol.
Table II Combinations tested
Combinations n
A + Dnr (AraC + Daunorubicin) 44
A+ Am (AraC + Amsa) 44
A + Mit (AraC + Mitoxantrone) 44
DAT (AraC + Doxorubicin + 6-thioguanine) 42
APV (AraC + Vincristine + Prednisolon) 42
MEA (AraC + VP16 + Mitoxantrone) 37
AVAm (AraC + VP16 + Amsa) 37
AraC + VP16 14
VP16 + Mit 14
Amsa + Mit 14
VP16 + Amsa 14
aConcentrations fortheindividual components used are EDCC listed
in Table I.
FMCA procedure
The principal steps of the assay procedure have been de-
scribed previously (Larsson et al., 1992a; Larsson & Nygren,
1990). Day 1 180pl of the leukaemia preparation at 2.5-5 x
10' cells ml-' in culture medium were seeded into the wells of
V-shaped 96 well experimental microtiter plates (Nunc, Ros-
kilde, Denmark) prepared as described above. Six blank wells
received only culture medium and six wells with cells, but
without drugs served as control. The culture plates were then
incubated at 37C in humidified atmosphere containing 95%
air and 5% CO2 for 72 h. At the end of the incubation
period the plates were centrifuged (200g, 7 min) and the
medium removed by flicking the plate. After one wash with
PBS, 200pl of PBS containing FDA (10,l ml-') was added
columnwise to control, experimental and blank wells. Subse-
quently the plates were incubated for 1 h before reading the
fluorescence in a Fluoroscan 2. The fluorometer was blanked
against wells containing PBS including the fluorescent dye
but without cells. The results obtained by the indicator FDA
are presented as survival index (SI) defined as fluorescence in
per cent of control cultures (Indicator test/Indicator control,
with blank values subtracted). Quality criteria for a success-
ful assay included an FDA signal in control cultures of
> 5 x mean blank values, mean CV in control cultures of
<30% and >80% of leukaemic cells prior to incubation.
Models ofdrug interactions in vitro
Two models of combination chemotherapy were tested essen-
tially according to the 'multiplicative' concept of drug
interactions (Valeriote & Lin, 1975) and to the procedure and
terminology used previously by Sondak et al. for in vitro
testing of solid tumours (Sondak et al., 1988a). The observed
SI values of the combination were plotted against that
predicted by two models. In the first model, termed
'additive', the effect of the combination is expected to be
equal to the product of the effect of its constituents. Thus, a
two-drug combination composed of single agents with SI
values of 50 and 40%, the combination would be expected to
result in a SI value of 20% (0.5 x 0.4 = 0.2). In the second
model, termed 'Dmax', the combination is expected to pro-
duce no greater effect than the most active single agent
(Dmax) alone, thus the effect of the combination = Dmax.
Observed values for combinations falling between these two
models would represent sub-additive effects whereas those
falling above Dmax would indicate true antagonism. Synergy
was defined as values falling below those predicted by the
additive model (Valeriote & Lin, 1975). In some analysis of
the data, the ratio of observed SI values and those expected
according to the additive model was plotted and observed/
expected ratios 1 ± 0.2 were arbitrarily defined as additive
interactions (Lepri et al., 1991).
Statistical analysis
The two models were compared using the non-parametric
sign test. For each sample tested, the absolute value (SIa) of
(/SIa/) the difference between the observed effect of the drug
combination (SI,bs) and that predicted by each model (SIp,d)
was calculated: Slpred-SIobs = /SIa/. The value obtained for
the Dmax model (/SlaDmax/) was then subtracted from the
value obtained for the additive model; (/SIaadd/): /Slaadd/- /
SIaDmax/. A negative value would consequently indicate that
the additive model is more accurate in predicting the
observed result. The sign test was then used to determine if
one model was significantly more likely to predict the
observed result after excluding ties. The level of significance
was set to P<0.05.
In vitro-in vivo comparison
Patients were treated according to local protocols without
knowledge of assay results. In vivo response was defined as
complete response (CR) as previously described (Larsson et
al., 1992a). The patients included for correlation were those
receiving relevant combination therapy with curative intent
and in which a clear documentation of clinical response were
available. The single agent in vitro-in vivo comparisons were
based on the sensitivity of the most active single agent
actually given in vivo. Correlations were performed at a
previously specified concentration producing a significant
scatter of SI values (Larsson et al., 1992a) using either a fixed
cut-off line (SI = 40%) determined from comparison with
previous results using the differential staining cytotoxicity
assay (Larsson et al., 1992b) or the use of drug specific
relative cut-off lines (median and median + 1 standard devia-
tion (s.d.; Kern & Weisenthal, 1990; Bosanquet, 1991). Using
the latter approach the SI values were positioned in relation-
ship to the sensitivity of all other samples in the present
study where low drug resistance (LDR) denotes SI values
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median but <1 s.d. and extreme drug resistance (EDR)
which denotes SI values>median + 1 s.d. (Kern & Weisen-
thal, 1990; Bosanquet, 1991).
Results
Effect ofdrug combinations
In Figure 1 the percentile distribution of SI values is shown
for each drug (a) and the combinations investigated (b). Each
bar encompasses 90% of the observations. The median is
indicated by the solid line whereas the broken lines delimits
25% of the observations. The median value is lower for all
combinations compared to the most active single component.
Type ofinteractionfor different combinations
In Figure 2 the expected SI values are plotted against those
observed for the AraC + Amsa and APV combinations. A
large variability is not only noted between individual samples
(Figure 2) but also observed for individual samples in re-
sponse to different combinations (Figure 3). For AraC +
Amsa the additive model provides a better distribution of
points about the line of identity whereas the opposite is true
for the APV combination. When the models were statistically
compared using the sign test, the additive model provided a
preferable fit for AraC + Amsa, MEA and AraC + Dnr
(P<0.05; Table III). The Dmax model was superior only in
the case of APV (P<0.05) whereas no preference for either
model was evident for the remaining combinations (non-
significant; Table III). In an attempt to investigate which of
the individual components that contributed most to the
efficacy of MEA, a second series of experiments (n = 14) was
performed with seven two-drug combinations (Figure 3). The
results show that VP16 + Mit was the far most active two-
drug combination in terms of additive and synergistic
interactions (Figure 3). In eight out of 14 samples (57%) the
interaction was synergistic compared to two of 14 (14%) and
four of 14 (29%) for AraC + VP16 and AraC + Mit, respec-
tively (Figure 3).
Use ofDmaxforprediction ofcombination activity
The accuracy of the most effective single agent in predicting
the in vitro activity of the combination using an SI value of
<40% as for separation of sensitive from resistant is shown
in Table IV. Of the 290 tests on combinations, 248 (85%)
showed an agreement between in vitro results of the best
single agent and the combination. The false negative rate was
12%. It should be noted that in 61% of the false negatives,
the SI value of the most active single agent were >40 but
<50% (not shown).
Relationship to clinical outcome
When the two interaction models were related to treatment
outcome (n = 23) three out of eight (38%) of the non-
responders showed preference for the additive model whereas
the corresponding figure for patients responding to given
combination therapy was 12 out of 15 (80%; Table V).
Direct comparison of Dmax and the combination for correla-
tion with clinical outcome using a 40% cut-off line revealed a
false positive (SR) rate of 25 and 38% for Dmax and the
combination, respectively (Table V). The corresponding
values for the false negative (RS) rate was 20 and 13%. This
pattern was reversed when drug-specific cut-off lines (median
value) was used for separation of sensitivity and resistance.
The SR and RS rate was in this case 38 and 13 vs 25 and
20% for Dmax and the combination, respectively (Figure 4).
The total number of patients given a correct classification in
terms of true positives (SS), true negatives (RR), SR and RS
was 18/23 (78%) irrespective of cut-off lines employed or
whether Dmax or observed combination activity provided the
basis for the correlations (Figure 4, Table V).
Discussion
The additive model was statistically preferable in three out of
seven combinations tested by the sign test, including the
Dnr + AraC, which is empirically known to be one of the
clinically most active remission induction regimens (Marie &
Zittoun, 1991). For the APV combination, on the other
hand, the Dmax model more closely predicted the effect. This
is not surprising since Vcr and Pred has shown to be of little
value for remission induction in AML (Goldman & James,
1990) and is only marginally active in vitro at concentrations
which are clearly active in ALL (Larsson et al., 1992a). Fur-
thermore, when 6TG was added to an anthracycline + AraC
containing regimen (DAT), no preference between the models
was evident. This is compatible with the observation that no
difference in terms of clinical CR rate at remission induction
between AraC + anthracycline alone and the use of the same
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Figure 1 Effect of individual antileukaemic drugs (a) and their combinations (b, n = 36-44) at EDCC on SI in AML samples.
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Table III Comparison between Dmax and theadditivemodel fordrug
interactions
Sign Probability
Combinations - + - %P
A+Dnr 25 14 64 <0.05
A+Am 28 14 67 <0.05
A + Mit 17 25 40 n.s.
DAT 22 18 55 n.s.
APV 13 29 31 <0.05
MEA '24 12 67 <0.05
AVAm 21 15 58 n.s.
Statistical analysis performed using the sign test, see Materials and
Methods. n.s. = non-significant.
regimen in conjunction with 6TG has been established (Marie
& Zittoun, 1991). When the relationship to clinical outcome
was investigated it became apparent that patients responding
to therapy showed a higher preference for the additive model
compared to Dmax whereas the opposite was true for
patients not responding to therapy. The fact that non-
responders showed preference for the Dmax model is in
accordance with the study of Sondak in which the majority
of samples were from drug resistant tumours where activity
and interactions of multiple drugs are expected to be at a
minimum. The responding patient population, on the other
hand, is drug sensitive and the probability for true drug
interactions is consequently expected to be higher. However,
one should also note that the frequency of additive interac-
tions in the present study may be underestimated in com-
parison with the report of Sondak et at. due to the different
endpoints used (cell viability vs cell proliferation).
One especially interesting observation concerns the fact
that the addition of VP16 to the AraC + Mit combination
makes this combination more predictable by the additive
compared to the Dmax model. This potential drug interac-
tion has been exploited clinically in Mit + VP16 + AraC con-
taining regimens with good clinical CR rate also in relapsed
and refractory patients (Amadori et at., 1991; Bjorkholm et
at., 1990; Link et at., 1990). Furthermore, we have recently
shown that AraC, Mit and VP16 appears to be mutually
non-cross resistant in vitro in AML samples (Kristensen et
al., 1992) which may indicate additional mechanisms of resis-
tance other than the 'classical' multidrug resistance pheno-
type or alterations of topoisomerase 2. The important
interaction may be between VP16 and Mit, since the addition
of VPl16 to an Amsa + AraC combination shifts the
preference of the additive model to non-significance. Further-
more, the direct testing of VPl16 + Mit showed the highest
frequency of synergistic interactions among all tested two-
drug combinations, including Arac + Mit and AraC + VP 16.
Good results in refractory leukaemia has been obtained with
the VP16 + Mit combination (Ho et at., 1988; Lazzarino et
at., 1989). This observation may become of clinical impor-
tance and indicate the feasibility of FMCA to detect drug
interactions in fresh tumour cell samples from patients with
leukaemia.
However, extrapolation of in vitro results have to be done
with care since important differences exist between in vitro
systems and the in vivo situation with respect to drug interac-
tions. First, it is important to note that even subadditive
effects at the cellular level may translate into therapeutically
beneficial interactions in vivo (Valeriote & Lin, 1975). Second,
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Table IV Correlation between the activity of the most active agent
(Dmax) and the combination
Dmax/comb No. ofsamples %
Sensitive/Sensitive 182 62
Sensitive/Resistant 8 3
Resistant/Sensitive 34 12
Resistant/Resistant 66 23
Totals 290 100
An SI value of40% was used for separation ofsensitive samples from
resistant ones.
tumour cells are exposed to high drug concentrations in vitro
(in most cases equivalent to peak plasma levels) which gives
much higher concentration x time products (CXT) than
obtained in vivo. However, this may not be the case for all
drugs. For example, bioassay determinations of Dox have
shown similar half lifes in vitro and in vivo (Hildebrandt-
Zanki & Kern, 1986). For the majority of antineoplastic
drugs, the in vitro assay CXT:s of active drug have not been
determined. Third, each drug was tested at a single concen-
tration only, due to limited availability of cells. Optimally,
testing a range of concentrations allowing formal isobolo-
gram analysis to be performed would yield more information
on subtle drug interactions (Berenbaum, 1989). Fourth, no
attempt was made to reproduce the scheduling employed in
various drug combinations. However, the significance of
scheduling and cell cycle specific interactions has not been
established for most clinically employed drug combinations
and the relevance of these phenomena to the current study
remains uncertain.
Single agents were also tested for their ability to predict
the effect of a combination. This has important implications
for drug sensitivity testing using in vitro assays since in most
cases drug combinations are not tested. Drug interactions
adhering to the additive model would in this case be expected
to cause false-negative in vitro/in vivo correlations. In the
majority of cases the most active single agent correctly
Table V Relationship of the interaction models to clinical outcomea
Pat Best Correlation
no. Treatment Result model Dmax Combination
1 AraC + Dnr NR Dmax RR RR
2 AraC + Dnr NR Additive RR SR
3 AraC + Mit NR Dmax RR RR
4 AraC + Dnr NR Additive RR RR
5 DAT + Vcr NR Additive SR SR
6 AraC + Dnr NR Dmax RR RR
7 AraC + Mit NR Dmax SR SR
8 AraC + Dnr NR Dmax RR RR
9 AraC + Amsa CR Additive SS SS
10 DAT + Vcr CR Dmax SS SS
11 AraC + Dnr CR Dmax SS SS
12 MEA CR Additive SS SS
13 AraC + Dnr CR Dmax SS SS
14 MEA CR Additive SS SS
15 AraC + Dnr CR Additive SS SS
16 MEA CR Additive SS SS
17 AraC + Dnr CR Additive SS SS
18 AraC + Dnr CR Additive RS RS
19 AVAm CR Additive RS RS
20 AraC + Dnr CR Additive RS SS
21 AraC + Dnr CR Additive SS SS
22 AraC + Dnr CR Additive SS SS
23 AraC + Dnr CR Additive SS SS
aPatients listed are those treated with combination therapy with
curative intent and where clinical data was evaluable for correlation.
NR = Nonresponders and CR = complete response according to the
definitions in Materials and methods. Best model refers to the
interactionmodel which was mostaccurate inpredictingtheeffectofthe
combination as described in Materials and methods. SS= true
positives, SR = false positives, RR = true negatives, RS = false
negatives. A 40% cut-off limit was used for separation of in vitro
sensitivity and resistance. For patient 5 and 10 who received Vcr in
addition to DAT, thelattercombination(DAT) wasused forthe in vitro
predictions.
predicted the in vitro activity of the combination, based on a
40% SI cut-off limit for discriminating sensitive from resis-
tant (Larsson et al., 1992b). Thus, in 15% of the cases the974 R. LARSSON et al.
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Figure 4 Dmax (0) or combination activity (0) as the basis for
correlation to clinical outcome (n = 23) using drug specific
relative cut-off lines. The median value separates LDR from IDR
and median + 1 s.d. separates IDR from EDR (Weisenthal &
Kern, 1990; Bosanquet, 1991). See Materials and methods.
Overall response rate was 65%.
activity of the most active single agent failed to predict the
combination. The testing of combinations may thus be
required in order to achieve maximal predictive accuracy.
However, comparison of direct clinical correlations based on
combinations vs single agents showed no apparent advantage
using the former approach. Although the tendency to pro-
duce false positive over false negative results varied in
opposite directions for correlation procedures based on
Dmax vs combination activity depending on which type of
cut-off limit was used, the overall predictive ability was
similar. Using the relative cut-off lines, the same EDR cases
could be identified with both methods. It should be noted
that 62% of the false negatives had SI values for most active
single agent activity of <50% suggesting that effective com-
binations requires active components. Additive and synergis-
tic interactions may thus be more important for predictions
of cure and survival than for predicting CR. This possibility
is currently investigated.
This study was supported by grants from the Swedish Cancer Society
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